Clinical trials: Malignant Pleural Mesothelioma
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this…
- Trial name
- NCT00165503
- Testing
- Cisplatin, Sodium Thiosulfate, ALIMTA
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Context Therapeutics Inc.
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
This phase II trial is studying how well EF5 works in detecting oxygen level and blood vessels in tumor cells of patients who are undergoing photodynamic therapy for intraperitoneal or pleural cancer.
- Conditions
- Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Malignant Ascites, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028782
- Testing
- etanidazole, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Mesotheliomas Pleural
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural…
- Trial name
- NCT03760575
- Testing
- Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
MALIGNANT PLEURAL MESOTHELIOMA
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.
- Trial name
- NCT00867711
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Clinico Humanitas
Pleural Mesothelioma, Non-small Cell Lung Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: To confirm the dose and to assess the safety profile of SAR444245 when…
- Trial name
- NCT04914897
- Testing
- THOR-707, Pembrolizumab
- Where
- 35 sites in United States, Argentina and 9 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Mesothelioma, Mesothelioma; Lung
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Purpose of the study: The main purpose of this research study is to see if a surgery procedure (limited partial pleurectomy and decortication) helps symptoms in people who have cancer that is unresectable that might not be able…
- Conditions
- Mesothelioma, Mesothelioma; Lung, Mesotheliomas Pleural, Mesothelioma Malignant Advanced
- Trial name
- NCT07126509
- Testing
- Partial Pleurectomy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Mesothelioma, Mesotheliomas Pleural
A Study of Sacituzumab Govitecan in People With Mesothelioma
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
- Trial name
- NCT06477419
- Testing
- Sacituzumab govitecan-hziy
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Malignant (Pleural) Mesothelioma
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients.
- Trial name
- PMR-MM-002 (NCT01241682)
- Testing
- DC + CTX
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Pleural Neoplasms, Mesothelioma
The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) has a growing incidence and in spite of early diagnostic, their outcome remains dismal. The evolution of MPM is often local with rare distant metastases.
- Conditions
- Pleural Neoplasms, Mesothelioma, Pneumothorax, Parathyroid Neoplasms
- Trial name
- NCT01776385
- Testing
- Blood sampling, Control Group
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Mesotheliomas Pleural
dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
The ENSURE trial is an open label, single center, phase 1, feasibility study. Sixteen adult patients diagnosed with resectable epithelioid malignant pleural mesothelioma (MPM) will be enrolled following first-line chemotherapy.
- Trial name
- ENSURE (NCT05304208)
- Testing
- Mesopher
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Erasmus Medical Center
Malignant Pleural Mesothelioma
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5.
- Trial name
- 1716-12 (NCT01721018)
- Testing
- HSV1716 Intra-pleural delivery
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Virttu Biologics Limited
Mesothelioma
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage IV mesothelin overexpressing malignant pleural mesothelioma (MPM).
- Trial name
- NCT02610140
- Testing
- Anetumab ravtansine (BAY94-9343), Vinorelbine
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 248 people
- Sponsor
- Bayer
Mesotheliomas Pleural
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be…
- Trial name
- AtezoMeso (NCT04996017)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection
- Where
- 19 sites in Italy
- Volunteers
- 162 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Pleural Malignant Mesothelioma
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA.
- Trial name
- NCT01112293
- Testing
- GC1008
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.